Boehringer Ingelheim Korea & Lilly Korea
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
Exhibition Item
Jardiance
Lilly Korea is a pharmaceutical company specializing in therapeutics with a 100% stake in Eli Lilly, a world-class R&D-oriented pharmaceutical company. In 1982, it entered Korea as Daewoong Lilly, a joint venture between Eli Lilly and Daewoong Pharmaceutical, and in 1998, it was newly launched as Korea Lilly and has continued to grow. Lilly Korea is doing its best to prolong life and improve the quality of life of Koreans by supplying innovative treatments in Korea in various areas such as diabetes, cancer, immune diseases, and pain.
Satellite Symposium
Lunchtime Activities
Empagliflozin’s Winning Trajectory in Heart Failure
Organized by CVRF and Supported by Educational Grant from Yuhan Corporation & Boehringer Ingelheim & Lilly Korea
Tuesday, May 9
12:30 PM ~ 1:30 PM * KST (UTC/GMT +9:00)
Presentation Theater 1, Vista 3, B2
Moderator(s): Weon Kim
Panelist(s): Hyo-Suk Ahn, Hyo-In Choi
| 12:30 PM | Jardiance, The First Successful Result for Heart Failure with Preserved Ejection Fraction Lecturer: Wonjae Lee |
| 12:50 PM | Should Jardiance be Used as 1st Essential Medication for Heart Failure, Regardless of LVEF? Lecturer: Kyung Hoon Cho |
| 1:10 PM | Discussion with Q&A |